KRSNAA · NSE
Krsnaa Diagnostics Limited
₹541.15
+0.02% (+₹0.1)
Prev. close
₹541.05
Volume
1,21,588
Delivery %
36.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Krsnaa Diagnostics Limited
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers mammography, stress tests, dual-energy X-ray absorptiometry scans, bone mineral density tests, computed tomography scans, and magnetic resonance imaging services, as well as tele-radiology and tele-pathology services. The company was incorporated in 2010 and is based in Pune, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Rajendra Khivraj Mutha
Headquarters
Pune
Employees
3,296
Website
krsnaadiagnostics.comExchange
View on NSE ↗Key stats
Market cap
₹1,755.42 Cr
P/E ratio (TTM)
18.3
Dividend yield
0.37%
EPS (TTM)
₹29.65
Beta (1Y · daily vs NIFTY 50)
0.93
Beta (5Y · monthly vs NIFTY 50)
0.62
Shares float
1.68 Cr
EPS · quarter ended Jun 2026
₹5.04
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹455.45 Cr | ₹487.12 Cr | ₹619.63 Cr | ₹717.16 Cr | ₹772.77 Cr | |
| EBITDA | — | ₹146.39 Cr | ₹141.68 Cr | ₹161.04 Cr | ₹215.66 Cr | ₹255.26 Cr |
| — | ₹68.00 Cr | ₹62.11 Cr | ₹56.84 Cr | ₹77.61 Cr | ₹101.43 Cr | |
| Diluted EPS | — | ₹22.88 | ₹19.29 | ₹17.31 | ₹23.56 | ₹30.88 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹609.28 Cr | ₹875.00 Cr | ₹908.00 Cr | ₹1,170.00 Cr | ₹1,278.00 Cr | ₹1,824.00 Cr | |
| ₹231.78 Cr | ₹40.99 Cr | ₹32.48 Cr | ₹159.79 Cr | ₹203.53 Cr | ₹534.32 Cr | |
| Stockholders' equity | ₹231.87 Cr | ₹685.00 Cr | ₹739.00 Cr | ₹810.00 Cr | ₹883.00 Cr | ₹980.00 Cr |
Current assets, Trade receivables, Non-current assets, Fixed assets, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹128.00 Cr | ₹76.00 Cr | ₹24.00 Cr | ₹87.00 Cr | ₹143.00 Cr | |
| Investing cash flow | — | ₹-240.64 Cr | ₹-108.89 Cr | ₹-128.88 Cr | ₹-99.61 Cr | ₹-395.99 Cr |
| — | ₹176.00 Cr | ₹-33.00 Cr | ₹84.00 Cr | ₹14.00 Cr | ₹279.00 Cr | |
| Capital expenditure | — | ₹-132.00 Cr | ₹-141.00 Cr | ₹-194.00 Cr | ₹-127.00 Cr | ₹-219.00 Cr |
| End cash position | ₹24.68 Cr | ₹88.45 Cr | ₹22.72 Cr | ₹2.38 Cr | ₹3.85 Cr | ₹30.22 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 22(4Q) | Sep 22–Sep 23(5Q) | Dec 23–Mar 24(2Q) | Jun 24–Sep 24(2Q) | Dec 24–Mar 25(2Q) | Jun 25–Jun 26(5Q) |
|---|---|---|---|---|---|---|
| Promoter | 27.38% | 27.80% | 27.03% | 27.17% | 27.24% | 27.11% |
| Public | 72.62% | 72.20% | 72.97% | 72.83% | 72.76% | 72.89% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Krsnaa Diagnostics Limited | ₹1,755.09 Cr | ₹541.15 | 18.2 | 1.79 | 10.3% | 0.55 | +7.8% | -36.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.